| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
tumor protein p53 | 0.236 | 0.962 | 0.53 |
|
phenotype | 0.100 | None | 0.962 | 1455 | 23 | 1990 | 2020 | ||||||||
|
APC regulator of WNT signaling pathway | 0.373 | 0.962 | 1.00 |
|
phenotype | 0.100 | None | 0.964 | 195 | 7 | 1990 | 2020 | ||||||||
|
epidermal growth factor receptor | 0.295 | 0.885 | 0.37 |
|
phenotype | 0.100 | None | 0.967 | 360 | 5 | 1986 | 2020 | ||||||||
|
8-oxoguanine DNA glycosylase | 0.453 | 0.808 | 3.9E-12 |
|
phenotype | 0.100 | None | 1.000 | 30 | 5 | 1998 | 2019 | ||||||||
|
erb-b2 receptor tyrosine kinase 2 | 0.328 | 0.923 | 6.0E-03 |
|
phenotype | 0.400 | None | 0.971 | 245 | 4 | 1989 | 2020 | ||||||||
|
B-Raf proto-oncogene, serine/threonine kinase | 0.319 | 0.846 | 1.00 |
|
phenotype | 0.400 | None | 0.924 | 157 | 4 | 2003 | 2020 | ||||||||
|
cyclin dependent kinase inhibitor 2A | 0.300 | 0.885 | 0.39 |
|
phenotype | 0.400 | None | 0.920 | 364 | 3 | 1994 | 2019 | ||||||||
|
KRAS proto-oncogene, GTPase | 0.320 | 0.923 | 7.9E-04 |
|
phenotype | 0.400 | None | 0.959 | 268 | 3 | 1990 | 2020 | ||||||||
|
ALK receptor tyrosine kinase | 0.396 | 0.846 | 3.2E-06 |
|
phenotype | 0.100 | None | 0.960 | 75 | 3 | 1997 | 2019 | ||||||||
|
secreted phosphoprotein 1 | 0.353 | 0.885 | 2.1E-06 |
|
phenotype | 0.100 | None | 0.982 | 56 | 3 | 2002 | 2019 | ||||||||
|
KIT proto-oncogene, receptor tyrosine kinase | 0.366 | 0.808 | 0.98 |
|
phenotype | 0.100 | None | 0.976 | 42 | 3 | 1994 | 2020 | ||||||||
|
cytochrome P450 family 1 subfamily A member 1 | 0.436 | 0.846 | 1.1E-17 |
|
phenotype | 0.100 | None | 1.000 | 40 | 3 | 1981 | 2019 | ||||||||
|
X-ray repair cross complementing 6 | 0.552 | 0.769 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 11 | 3 | 2002 | 2015 | ||||||||
|
intercellular adhesion molecule 1 | 0.364 | 0.962 | 3.5E-02 |
|
phenotype | 0.100 | None | 1.000 | 11 | 3 | 1997 | 2019 | ||||||||
|
NFKB inhibitor alpha | 0.487 | 0.885 | 0.99 |
|
phenotype | 0.070 | None | 1.000 | 7 | 3 | 2003 | 2016 | ||||||||
|
ADP ribosylation factor like GTPase 11 | 0.670 | 0.423 | 5.3E-03 |
|
phenotype | 0.030 | None | 1.000 | 3 | 3 | 2006 | 2008 | ||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
phenotype | 0.010 | None | 1.000 | 1 | 3 | 2017 | 2017 | |||||||||
|
BRCA1 DNA repair associated | 0.367 | 0.923 | 9.2E-29 |
|
phenotype | 0.100 | None | 0.976 | 208 | 2 | 1994 | 2020 | ||||||||
|
MDM2 proto-oncogene | 0.362 | 0.846 | 1.00 |
|
phenotype | 0.100 | None | 0.971 | 173 | 2 | 1994 | 2020 | ||||||||
|
estrogen receptor 1 | 0.324 | 0.962 | 1.00 |
|
phenotype | 0.100 | None | 0.973 | 146 | 2 | 1997 | 2019 | ||||||||
|
enhancer of zeste 2 polycomb repressive complex 2 subunit | 0.376 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 0.993 | 135 | 2 | 2004 | 2020 | ||||||||
|
epidermal growth factor | 0.357 | 0.923 | 8.5E-17 |
|
phenotype | 0.100 | None | 0.989 | 94 | 2 | 1990 | 2019 | ||||||||
|
HRas proto-oncogene, GTPase | 0.378 | 0.885 | 8.0E-02 |
|
phenotype | 0.100 | None | 0.936 | 78 | 2 | 1985 | 2018 | ||||||||
|
peroxisome proliferator activated receptor gamma | 0.358 | 0.885 | 2.9E-02 |
|
phenotype | 0.100 | None | 0.973 | 73 | 2 | 1999 | 2019 | ||||||||
|
EPH receptor B2 | 0.374 | 0.846 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 67 | 2 | 1994 | 2019 |